Get the Stockscreener App
22.75
2.27%
0.4576
Vera Therapeutics Inc stock is traded at $22.75, with a volume of 105.85K.
It is up +2.27% in the last 24 hours and up +5.29% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$22.29
Open:
$22.66
24h Volume:
105.85K
Relative Volume:
0.06
Market Cap:
$1.45B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-10.29
EPS:
-2.21
Net Cash Flow:
$-106.82M
1W Performance:
-3.25%
1M Performance:
+5.29%
6M Performance:
-33.13%
1Y Performance:
-35.00%
1-Day Range:
$22.29
$23.30
1-Week Range:
$22.09
$24.03
52-Week Range:
$18.53
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
22.76 | 1.48B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.64 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.50 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.57 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.50 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.73 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
What analysts say about Vera Therapeutics Inc. stockDynamic investment opportunities - Autocar Professional
What drives Vera Therapeutics Inc. stock priceFree Trading Strategy Suggestions - Autocar Professional
Vera Therapeutics Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
Is Vera Therapeutics Inc. a good long term investmentBreakthrough profit margins - jammulinksnews.com
Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com
Fund Remains in Vera Therapeutics Short-Swing Trading Lawsuit - Bloomberg Law News
Vera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA Nephropathy - MSN
how vera therapeutics inc. stock performs during market volatilityFree Deep Market Trend Analysis - Newser
How Vera Therapeutics Inc. stock performs during market volatilityReal Chart Play - Newser
What makes Vera Therapeutics Inc. stock price move sharplyFree Stock Market Forums - Newser
Why Vera Therapeutics Inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Vera Therapeutics announces refinancing of Oxford debt facility with access to up to $500M in term loans - MSN
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Expands Team with 200K+ Shares in Stock Options and RSUs for New Hires - Stock Titan
Polycythemia Vera Clinical Trials 2025: EMA, PDMA, FDA - openPR.com
How to Take Advantage of moves in (VERA) - news.stocktradersdaily.com
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
Vera Therapeutics (VERA): Insider Buying and Clinical Breakthroughs Signal a Golden Opportunity - AInvest
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load? - simplywall.st
Hedge Fund and Insider Trading News: Bill Ackman, Steve Cohen, Ray Dalio, Philippe Laffont, David Tepper, Whale Rock Capital Management, Vera Therapeutics Inc (VERA), Pinterest Inc (PINS), and More - Insider Monkey
Vera Therapeutics director Enright buys shares worth $5.2m - Investing.com
Vera Therapeutics Inc put volume heavy and directionally bearish - TipRanks
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat
Transcript : Vera Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 03 - marketscreener.com
Vera Therapeutics (VERA) Sees Surge in Bullish Options Activity | VERA Stock News - GuruFocus
Vera Therapeutics reports inducement grants under Nasdaq listing rule - MarketScreener
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vera Therapeutics Inc Stock (VERA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ENRIGHT PATRICK G | Director |
Jun 24 '25 |
Buy |
22.35 |
40,607 |
907,635 |
3,596,593 |
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 21 '25 |
Sale |
27.89 |
10,613 |
296,032 |
213,740 |
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
4.47%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):